Fig. 7From: Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohortOS in three different risk groups (good, average, poor) stratified at the 33rd and 66th percentiles of model predicted outcomesBack to article page